Amgen | AMGN

Stock Price
348.45
Daily Change
-1.32 -0.38%
Monthly
-9.34%
Yearly
13.55%
Q1 Forecast
337.37

Date Reference Time Actual Consensus Previous
2026-04-29 FY2026Q1 PM 4.79 4.90
2026-02-03 FY2025Q4 PM 5.29 4.72 5.31
2025-11-04 FY2025Q3 PM 5.64 5.07 5.58
2025-08-05 FY2025Q2 PM 6.02 5.23 4.97
2025-05-01 FY2025Q1 PM 4.90 4.73 3.96



Peers Price Chg Day Year Date
Takeda 5,815.00 152.00 2.68% 28.25% Mar/25
AbbVie 205.22 0.29 0.14% 1.93% Mar/24
Agios Pharmaceuticals 28.35 0.24 0.85% -7.83% Mar/24
ALKERMES 28.39 0.68 2.45% -16.20% Mar/24
Amgen 348.45 -1.32 -0.38% 13.55% Mar/24
Biogen 183.94 0.30 0.16% 32.18% Mar/24
BioMarin Pharmaceutical 54.10 -0.68 -1.24% -24.37% Mar/24
Bristol-Myers Squibb 57.38 0.38 0.67% -3.06% Mar/24
Coherus Biosciences 1.71 0.07 4.27% 78.13% Mar/24
Exelixis 41.57 0.16 0.39% 10.24% Mar/24

Indexes Price Day Year Date
US500 6601 -24.63 -0.37% 15.56% Mar/25
USND 21762 -184.87 -0.84% 19.10% Mar/24
US30 46493 -84.41 -0.18% 9.51% Mar/25
US100 24198 -186.14 -0.77% 21.49% Mar/25

Amgen traded at $348.45 this Tuesday March 24th, decreasing $1.32 or 0.38 percent since the previous trading session. Looking back, over the last four weeks, Amgen lost 9.34 percent. Over the last 12 months, its price rose by 13.55 percent. Looking ahead, we forecast Amgen to be priced at 337.37 by the end of this quarter and at 307.90 in one year, according to Trading Economics global macro models projections and analysts expectations.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.



News Stream
Amgen Stock Price Hits 4-week Low
Amgen shares decreased to 361.38 USD, the lowest since February 2026. Over the past 4 weeks, Amgen lost 4.79%, and in the last 12 months, it increased 13.46%.
2026-03-17
Amgen Stock Price Hits All-time High
Amgen shares increased to an all-time high of 390.29 USD. Over the past 4 weeks, Amgen gained 13.66%, and in the last 12 months, it increased 26.26%.
2026-03-02
Amgen Stock Price Hits All-time High
Amgen shares increased to an all-time high of 355.51 USD. Over the past 4 weeks, Amgen gained 5.57%, and in the last 12 months, it increased 17.15%.
2026-02-04